Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lowered by Voleon Capital Management LP

Voleon Capital Management LP lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,914 shares of the biopharmaceutical company’s stock after selling 25,267 shares during the quarter. Voleon Capital Management LP’s holdings in Alnylam Pharmaceuticals were worth $3,217,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $69,292,000. Adage Capital Partners GP L.L.C. increased its stake in Alnylam Pharmaceuticals by 203.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock valued at $76,195,000 after buying an additional 189,128 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after buying an additional 185,783 shares during the period. Finally, GAMMA Investing LLC increased its stake in Alnylam Pharmaceuticals by 30,759.4% in the 1st quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company’s stock valued at $44,913,000 after buying an additional 165,793 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ALNY shares. Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price target on the stock. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $417.38.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $452.00 on Monday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a fifty day simple moving average of $387.47 and a 200 day simple moving average of $310.11. The company has a market cap of $59.25 billion, a P/E ratio of -183.00 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 31,448 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares of the company’s stock, valued at approximately $397,724.38. This trade represents a 97.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the sale, the chief executive officer owned 56,221 shares of the company’s stock, valued at $25,483,292.67. This trade represents a 11.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 57,594 shares of company stock worth $25,551,456 in the last ninety days. Company insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.